Treatment of Plasmodium falciparum malaria with quinine in children in Guinea-Bissau:: one daily dose is sufficient

被引:5
作者
Kofoed, PE [1 ]
Có, F
Poulsen, A
Cabral, C
Hedegaard, K
Aaby, P
Rombo, L
机构
[1] Kolding Cty Hosp, Dept Paediat, DK-6000 Kolding, Denmark
[2] Projecto Saude Bandim, Bandim, Guinea Bissau
[3] Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, Copenhagen, Denmark
[4] Lab Nacl Saude Publ, Bissau, Guinea Bissau
[5] Div Infect Dis Thorac Med & Dermatol, Eskilstuna, Sweden
关键词
malaria; Plasmodium falciparum; chemotherapy; quinine; children; dose regimens; Guinea-Bissau;
D O I
10.1016/S0035-9203(02)90298-1
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
We have earlier obtained good results in falciparum malaria by treating children with low doses of quinine for 7 days in Guinea-Bissau. In order to further simplify treatment, we compared outcome in 100 children with falciparum. malaria treated in 1999/2000 for 7 days with 15 mg quinine salt/kg/dose twice daily (group 1), 100 children treated with 7.5 mg quinine salt/kg/dose twice daily (group II), and 100 children treated with one single daily dose of 15 mg/kg. On day 28, parasites had reappeared in 12%, 15%, and 9%, respectively. These results are similar to what has been found after previous successful treatment regimens. Apart from a higher incidence of vomiting during the first 24 h of treatment in the groups treated with 15 mg/kg/dose no significant differences in symptoms or side-effects were found between the groups. In patients suffering from uncomplicated malaria, treatment with quinine can be simplified to one single dose of 15 mg/kg bodyweight whenever logistics make 2 daily doses less feasible.
引用
收藏
页码:185 / 188
页数:4
相关论文
共 10 条
[1]   ESTIMATION OF THE PROPORTIONAL HAZARD IN 2-TREATMENT-GROUP CLINICAL-TRIALS [J].
BERNSTEIN, L ;
ANDERSON, J ;
PIKE, MC .
BIOMETRICS, 1981, 37 (03) :513-519
[2]   REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY DETERMINATION OF QUININE IN PLASMA, WHOLE-BLOOD, URINE, AND SAMPLES DRIED ON FILTER-PAPER [J].
ERICSSON, O ;
FRIDEN, M ;
HELLGREN, U ;
GUSTAFSSON, LL .
THERAPEUTIC DRUG MONITORING, 1993, 15 (04) :334-337
[3]  
KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES, P300
[4]   Comparison of 3, 5 and 7 days' treatment with Quinimax(TM) for falciparum malaria in Guinea-Bissau [J].
Kofoed, PE ;
Mapaba, E ;
Lopes, F ;
Pussick, F ;
Aaby, P ;
Rombo, L .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1997, 91 (04) :462-464
[5]   Low-dose quinine for treatment of Plasmodium falciparum malaria in Guinea-Bissau [J].
Kofoed, PE ;
Lopes, F ;
Johansson, P ;
Dias, F ;
Sandstrom, A ;
Aaby, P ;
Rombo, L .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1999, 93 (05) :547-549
[6]   SUSCEPTIBILITY OF PLASMODIUM-FALCIPARUM TO QUININE IN-VITRO - EFFECTS OF DRUG CONCENTRATIONS AND TIME OF EXPOSURE [J].
MAPABA, E ;
HELLGREN, U ;
LANDBERGLINDGREN, A ;
ROMBO, L .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1995, 89 (01) :85-89
[7]   Predictors of mefloquine treatment failure: A prospective study of 1590 patients with uncomplicated falciparum malaria [J].
terKuile, FO ;
Luxemburger, C ;
Nosten, F ;
Thwai, KL ;
Chongsuphajaisiddhi, T ;
White, NJ .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1995, 89 (06) :660-664
[8]  
White NJ, 1998, ANN TROP MED PARASIT, V92, P449, DOI 10.1080/00034989859429
[9]  
WHO, 1990, WHO TECHN REP SER, V805
[10]  
ZHANG MJ, 1999, ENCY BIOSTATISTICS, V2, P1786